by Stephanie Holmes | Oct 13, 2022 | Lupus Foundation of America, News & Events
In general, lupus disease activity generally declines with the initiation of renal replacement therapy (RRT). RRT includes treatments such as dialysis, whereby a person’s blood is filtered with or without machines due to poor kidney function. People with lupus...
by Stephanie Holmes | Oct 13, 2022 | Lupus Foundation of America, News & Events
New research out of Egypt reveals that the protein known as high‐mobility group box 1 protein (HMGB1) may be helpful in diagnosing lupus, planning treatment, and predicting lupus nephritis (LN, lupus-related kidney disease). This protein can activate the immune system...
by Stephanie Holmes | Oct 13, 2022 | Lupus Foundation of America, News & Events
A new study looked at available data on birth defects and loss of pregnancy (miscarriage or still-birth) in women who were using belimumab (Benlysta) for lupus treatment. Three data sources – clinical trial findings (18 total), the Belimumab Pregnancy Registry (BPR),...
by Stephanie Holmes | Oct 13, 2022 | Lupus Foundation of America, News & Events
Research results continue to confirm the positive benefit-risk profile of belimumab (Benlysta®), finding that the treatment does not significantly raise the risk of safety concerns compared to a placebo drug. These findings are consistent with previously reported...
by Stephanie Holmes | Oct 13, 2022 | Lupus Foundation of America
En Español We asked Dr. Cristina Drenkard to participate in a Q&A blog about health disparities and social determinants of health. Dr. Drenkard discusses what these terms mean and how it can affect people who have lupus in the Hispanic/Latino community. What are...
